News
MANE
129.66
-4.16%
-5.63
Veradermics, Incorporated (MANE) Receives a Buy from Leerink Partners
TipRanks · 1d ago
Veradermics to Present at the Jefferies Global Healthcare Conference in London
Barchart · 2d ago
Veradermics Price Target Raised to $175.00/Share From $160.00 by Citigroup
Dow Jones · 4d ago
Veradermics Is Maintained at Buy by Citigroup
Dow Jones · 4d ago
Citigroup Maintains Buy on Veradermics, Raises Price Target to $175
Benzinga · 4d ago
Veradermics price target raised to $175 from $160 at Citi
TipRanks · 4d ago
Veradermics: Q3 Earnings Snapshot
Barchart · 4d ago
Veradermics reports Q3 net loss ($21M) vs. ($20.1M) last year
TipRanks · 4d ago
Veradermics sees cash runway into 2030
TipRanks · 4d ago
Veradermics reports Q3 results
Seeking Alpha · 4d ago
*Veradermics on Track to Deliver Topline Data From Phase 2/3 Study '306' Evaluating VDPHL01 in Female Pattern Hair Loss in 1H27 >MANE
Dow Jones · 4d ago
*Veradermics 3Q Loss $21M >MANE
Dow Jones · 4d ago
Press Release: Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Dow Jones · 4d ago
Analysts Offer Insights on NA Companies: Veradermics, Incorporated (MANE), Bicara Therapeutics Inc. (BCAX) and Exodus Movement, Inc. Class A (EXOD)
TipRanks · 4d ago
Veradermics Price Target Raised to $150.00/Share From $135.00 by Leerink Partners
Dow Jones · 5d ago
Veradermics Is Maintained at Outperform by Leerink Partners
Dow Jones · 5d ago
Leerink Partners Maintains Outperform on Veradermics, Raises Price Target to $150
Benzinga · 5d ago
Veradermics Eyes Historic FDA First After Strong Hair Loss Pill Trial Results
Benzinga · 5d ago
Veradermics price target raised to $150 from $135 at Leerink
TipRanks · 5d ago
Veradermics Reports Positive Phase 2/3 Hair Loss Trial Results
TipRanks · 5d ago
More
Webull provides a variety of real-time MANE stock news. You can receive the latest news about VERADERMICS INC through multiple platforms. This information may help you make smarter investment decisions.
About MANE
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.